- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02609685
Active Surveillance of Papillary Thyroid Microcarcinoma (PMCAS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The incidence of thyroid cancer has more than doubled in the last 30 years in the United States, Europe, Canada, and South America. Since nearly 50% of this increase is attributable to papillary thyroid microcarcinomas (PTMC), it appears that greater detection and diagnosis of previously subclinical disease is a major factor driving this dramatic rise.
The primary objective is to estimate the rate of disease progression (growth of primary tumor or development of loco-regional/distant metastases) over a 3, 5, and 10-year period in a series of PTMC patients followed with active surveillance in the United States.
Patients who opt for immediate surgery can participate in a sub-study looking at quality of life and anxiety measures as compared to those patients who enroll in the active surveillance main study. Patients who enroll in active surveillance can choose to have surgery at any time that they and their treating physician feel that it is in their best interest.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Allen Ho, MD
- Phone Number: 310-423-1220
- Email: Allen.Ho@cshs.org
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Recruiting
- Cedars-Sinai Medical Center
-
Contact:
- Allen Ho, MD
- Phone Number: 310-423-1220
- Email: Allen.Ho@cshs.org
-
Principal Investigator:
- Allen Ho, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pathologically confirmed Bethesda V or VI thyroid nodules with papillary thyroid carcinoma or high clinical suspicion, or pathologically confirmed Bethesda III or IV nodules with BRAF mutation.
- 2.0 cm or smaller nodules by ultrasonographic criteria
- Ability to understand and the willingness to sign a written informed consent and HIPAA Authorization form
- Must be able to read and write English fluently to participate in the questionnaire portion of the study
Exclusion Criteria:
- High-grade or poorly differentiated PTC variants
- Central or lateral neck lymphadenopathy suspicious for PTC
- Unfavorable nodule location (e.g. Near dorsal surface (by recurrent laryngeal nerve); Adjacent to trachea (risk of cartilage invasion)
- History of radiation to neck
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Active Surveillance
Active surveillance instead of standard of care immediate surgery.
Patients will be closely monitored every six months until disease is stable for a two-year period and then annually thereafter.
|
Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.
|
No Intervention: Immediate Surgery
Patients who choose to get surgery immediately after diagnosis may choose to enroll in a questionnaire sub-study that will compare quality of life and anxiety scores to patients who enroll in the active surveillance study.
This is considered "no intervention" because the protocol is not directing treatment.
Surgery is the standard treatment for papillary thyroid microcarcinoma.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of disease progression
Time Frame: From time of diagnosis up to10 years of follow-up
|
From time of diagnosis up to10 years of follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of subjects that will elect surgery despite absence of clinical progression
Time Frame: From time of diagnosis up to 10 years of follow-up
|
From time of diagnosis up to 10 years of follow-up
|
|
Impact of TSH suppression on thyroid nodule growth (in cm) as measured by ultrasound
Time Frame: Five years
|
Five years
|
|
Identify the clinicopathologic features associated with disease progression in papillary thyroid microcarcinoma patients followed with active surveillance
Time Frame: Five years
|
Five years
|
|
Identify the genetic factors associated with an increased risk of disease progression
Time Frame: Five years
|
At any time subjects who have enrolled in the active surveillance study can opt to have surgery.
Data will be taken from diagnosis to just after surgery.
|
Five years
|
Quality of life score as measured by City of Hope Quality of Life Scale
Time Frame: Up to five years
|
Up to five years
|
|
Anxiety score as measured by Memorial Anxiety Scale
Time Frame: Up to five years
|
Up to five years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Allen Ho, MD, Cedars-Sinal Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIT2014-13-Ho-PMCAS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Papillary Thyroid Microcarcinoma
-
European Institute of OncologyRecruiting
-
National Cancer Institute, NaplesRecruitingPapillary Microcarcinoma of the ThyroidItaly
-
Mayo ClinicActive, not recruitingPapillary Thyroid Cancer | Papillary Thyroid MicrocarcinomaUnited States
-
University Health Network, TorontoUniversity of British Columbia; Canadian Institutes of Health Research (CIHR); CHU de Quebec-Universite Laval and other collaboratorsRecruitingPapillary Thyroid Carcinoma | Papillary Thyroid Cancer | Papillary Microcarcinoma of the ThyroidCanada
-
Yonsei UniversityCompletedPapillary Thyroid MicrocarcinomaKorea, Republic of
-
Seoul National University HospitalRecruitingThyroid Cancer | Papillary Thyroid MicrocarcinomaKorea, Republic of
-
Second Affiliated Hospital, School of Medicine,...RecruitingPapillary Thyroid MicrocarcinomaChina, Ukraine
-
Korean Association of Endocrine SurgeonsCompletedPapillary Thyroid MicrocarcinomaKorea, Republic of
-
Memorial Sloan Kettering Cancer CenterRecruitingThyroid | Thyroid Cancer | Papillary Thyroid MicrocarcinomaUnited States
-
Seoul National University HospitalActive, not recruitingThyroid Cancer | Papillary Thyroid MicrocarcinomaKorea, Republic of
Clinical Trials on Active Surveillance
-
University Health Network, TorontoActive, not recruiting
-
University of AlbertaCompleted
-
M.D. Anderson Cancer CenterRecruitingProstate CancerUnited States
-
Hospital Moinhos de VentoRecruiting
-
IRCCS San RaffaeleRecruiting
-
Uppsala UniversityRecruitingProstate CancerNorway, Denmark, Finland, United Kingdom, Sweden
-
Parker UniversityUniversity of Alberta; University of Texas at Tyler; Canadian Memorial Chiropractic...CompletedPatient Safety | Manipulation, Spinal
-
Anhui Provincial HospitalZhongda Hospital; Yijishan Hospital of Wannan Medical College; Wuhu City Second...Recruiting
-
Seoul National University HospitalRecruitingProstate CancerKorea, Republic of
-
Guy's and St Thomas' NHS Foundation TrustKing's College London; Uppsala UniversityActive, not recruiting